Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes: The GUSTO-IIb haemostasis substudy

European Heart Journal

Volumn 23, Issue 15, 2002, Pages 1202-1212

  Kottke Marchant, Kandice ^a   Bahit, M C ^b   Granger, C B ^b   Zoldhelyi, P ^c   Ardissino, D ^d   Brooks, L ^a   Griffin, J H ^e   Potthoff, R F ^b   Van De Werf, F ^f   Califf, R M ^b   Topol, E J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c TEXAS HEART INSTITUTE   (United States)

^d MAGGIORE HOSPITAL   (Italy)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Acute coronary syndromes; Haemostasis; Prognosis; Thrombin

Indexed keywords

DESULFATOHIRUDIN; FIBRINOPEPTIDE A; HEPARIN; HIRUDIN; PROTEIN C; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DEATH; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEART REINFARCTION; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; THROMBIN TIME;

ACUTE DISEASE; AGED; BLOOD COAGULATION; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HEART DISEASES; HEMOSTASIS; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; MALE; MIDDLE AGED; SYNDROME; THROMBIN; TREATMENT OUTCOME;

EID: 0036700408     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3074     Document Type: Article

References (25)

1. Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-40.
2. Davies M, Thomas A. Plaque fissuring: The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985; 53: 63-73.
3. Chesebro J, Fuster V. Thrombosis in unstable angina. N Engl J Med 1992; 327: 192-4.
4. Talbot MD, Ambler J, Butler KD et al. Recombinant desulfatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemost 1989; 61: 77-80.
5. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin vs recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-65.
6. Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 1989; 15: 269-82.
7. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after discontinuation of heparin. N Engl J Med 1992; 327: 141-5.
8. Granger CB, Hirsh J, Califf RM et al., for the GUSTO-I Investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I trial. Circulation 1996; 93: 870-8.
9. Granger CB, Miller J, Bovill EG et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995; 91: 1929-35.
10. Granger CB, Becker R, Tracy R et al., for the GUSTO-I Hemostasis Substudy Group. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the GUSTO-I trial. J Am Coll Cardiol 1998; 31: 497-505.
11. TRIM Study Group. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomised, dose-finding study. Eur Heart J 1997; 18: 1416-25.
12. Merlini PA, Bauer KA, Oltrona L et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
13. The GUSTO-IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
14. The GUSTO-IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
15. Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC hemostasis study-1. Development of blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989; 61: 15-9.
16. Gruber A, Griffin JH. Direct measurement of activated protein C in blood from human subjects. Blood 1992; 79: 2340-8.
17. Scharfstein JS, Abendschein DR, Eisenberg PR et al. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. Am J Cardiol 1996; 78: 503-10.
18. Rao AK, Sung L, Chesebro JH et al. Distinct effects of recombinant desulfatohirudin and heparin on plasma levels of fibrinopeptide A and prothrombin fragment Fl.2 in unstable angina: A multicenter trial. Circulation 1996; 94: 2389-95.
19. Flather M, Weitz J, Yusuf S et al. for the OASIS Pilot Study Group. Reactivation of the coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: Results of a randomised trial. Eur Heart J 2000; 21: 1473-81.
20. Merlini PA, Ardissino D, Rosenberg RD et al. In vivo thrombin generation and activity during and after infusion of heparin or recombinant hirudin in patients with unstable angina pectoris. Arterioscler Thromb Vasc Biol 2000; 20: 2162-6.
21. Shammas NW, Cunningham MJ, Pomerantz RM, Frances CW. Markers of hemostatic activation in affected coronary arteries during angioplasty. Thromb Haemost 1994; 72: 672-5.
22. Mascelli MA, Kleiman N, Marciniak SJ, Damaraju L, Weisman HF, Jordan RE. Therapeutic concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am Heart J 2000; 139: 696-703.
23. Mayo KH, Ilyina E, Roongta V et al. Heparin binding to platelet factor 4. An NMR and site-directed mutagenesis study: Arginine residues are crucial for binding. Biochem J 1995; 312: 357-65.
24. Linder R, Oldgren J, Egberg N et al. The effect of low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease. Eur Heart J 1999; 20: 506-18.
25. Ardissino D, Merlini PA, Gamba G et al. Thrombin activity and early outcome in unstable angina pectoris. Circulation 1996; 93: 1634-9.